タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	ここが知りたい血栓症治療の正解，不正解
出版社	中外医学社
発行日	2021-04-01
著者	後藤信哉(著)
ISBN	9784498134409
ページ数	114
版刷巻号	1版1刷
分野	臨床医学：内科血管
閲覧制限	未契約

患者にとっての「正しい治療」とはいったい何であろうか。著者が自らの専門領域である「血栓症」の治療(投薬)をテーマに、「正しい治療とは何か?」という医療の根本的な命題について若手医師に問いかける。EBMとは何か?診療ガイドラインの在り方やその読み方とは?臨床試験の意味とは?製薬会社の思惑とは?患者を幸せにする「正しい治療」とは何か?について、指導医、専攻医、研修医3名の会話によってわかりやすく解説。

目次

表紙
閲覧
序
閲覧
目次
閲覧
[ CHAPTER 1 ] 診療ガイドラインの推奨は「正しい」か ?
P.1閲覧
[ CHAPTER 2 ] 動脈系の血栓症と静脈系の血栓症から考える診断と治療の「正解」
P.11閲覧
- A : 動脈血栓症と静脈血栓症の違いは何か ?
- B : 静脈血栓症と「正しい」治療・薬剤選択
- C : 動脈血栓症と「正しい」治療・薬剤選択
[ CHAPTER 3 ] 臨床試験の意味
P.38閲覧
- A : なぜ, 臨床試験を行うのか ?
- B : 臨床試験の実際
[ CHAPTER 4 ] 人工知能とコンピュータのインパクト
P.76閲覧
- A : 人工知能の登場
- B : 人工知能の医療応用
- C : 高性能コンピュータの基盤整備により医療は変わる ?
- D : 帰納的論理と演繹的論理
- E : 若手医師もベンチャーマインドを
Key Phrase
P.103閲覧
奥付
閲覧

参考文献

目次

P.36 掲載の参考文献

1) DuBois JM, Chibnall JT, Anderson EE, et al. Exploring unnecessary invasive procedures in the United States : a retrospective mixed-methods analysis of cases from 2008-16. Patient Safety in Surgery. 2017 ; 11 : 30.
pubmed

2) Steg PG, Bhatt DL, Wilson PW, et al. Investigators RR. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297 : 1197-206.

3) Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010 ; 304 : 1350-7.
pubmed

4) Bassand JP, Virdone S, Goldhaber SZ, et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019 ; 139 : 787-98.
pubmed

5) Koretsune Y, Etoh T, Katsuda Y, et al. Investigators GA. Risk profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan-insights from GARFIELD-AF. Circ J. 2018 ; 83 : 67-74.

6) Karthikeyan G, Ananthakrishnan R, Devasenapathy N, et al. Transient, subclinical atrial fibrillation and risk of systemic embolism in patients with rheumatic mitral stenosis in sinus rhythm. Am J Cardiol. 2014 ; 114 : 869-74.
pubmed

7) Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke : the Framingham Study. Stroke. 1991 ; 22 : 983-8.
pubmed

8) Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 ; 120 : 700-5.
pubmed

9) Patel MR, Mahaffey KW, Garg J, et al. Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 : 883-91.

10) Granger CB, Alexander JH, McMurray JJ, et al. Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 : 981-92.
pubmed

11) Giugliano RP, Ruff CT, Braunwald E, et al. Investigators EAT. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 ; 369 : 2093-104.

12) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 : 1139-51.
pubmed

13) Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008 ; 156 : 855-63. e2.

14) Connolly SJ, Eikelboom J, Joyner C, et al. Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 ; 364 : 806-17.
pubmed

15) Patrono C, Rodriguez LAG, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 ; 353 : 2373-83.

16) Toyoda K, Yasaka M, Iwade K, et al. Bleeding with antithrombotic therapy study G. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke. 2008 ; 39 : 1740-5.

17) Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithromboticdrug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998 ; 339 : 1665-71.

18) Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345 : 494-502.
pubmed

[ CHAPTER 1 ] 診療ガイドラインの推奨は「正しい」か ?

P.74 掲載の参考文献

1) Goto S, Ikeda Y, Shimada K, et al. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J. 2011 ; 75 : 2598-604.
pubmed

2) Origasa H, Goto S, Shimada K, et al. Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin : rationale and design of the MAGIC Study. Cardiovasc Drugs Ther. 2011 ; 25 : 551-60.
pubmed

3) Uchiyama S, Goto S, Origasa H, et al. and Group MS. Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases : 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. Heart Vessels. 2020 ; 35 : 170-6.

4) Uemura N, Sugano K, Hiraishi H, et al. and Group MS. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients : the results from the MAGIC study. J Gastroenterol. 2014 ; 49 : 814-24.

5) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Committee R-LS and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 : 1139-51.

6) Patel MR, Mahaffey KW, Garg J, et al. Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 : 883-91.

7) Granger CB, Alexander JH, McMurray JJ, et al. Committees A and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 : 981-92.
pubmed

8) Giugliano RP, Ruff CT, Braunwald E, et al. Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 ; 369 : 2093-104.

9) Hori M, Matsumoto M, Tanahashi N, et al. Investigators JRAs. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J. 2012 ; 76 : 2104-11.

10) Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke : perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 ; 8 : e63479.
pubmed

11) Mucke S, Grotemeyer K-H, Stahlhut L, et al. The influence of fluid intake on stroke recurrence-A prospective study. J Neurol Scie. 2012 ; 315 : 82-5.

12) Hart RG, Sharma M, Mundl H, et al. Investigators NE. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018 ; 378 : 2191-201.

13) Diener HC, Sacco RL, Easton JD, et al. Committee R-SES and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019 ; 380 : 1906-17.

14) Alexander JH, Lopes RD, James S, et al. Investigators A-. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 ; 365 : 699-708.
pubmed

15) Mega JL, Braunwald E, Wiviott SD, et al. Investigators AAT. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 ; 366 : 9-19.

16) Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1) : a double-blind, multicentre, randomised trial. Lancet. 2017 ; 389 : 1799-808.

17) Eikelboom JW, Connolly SJ, Bosch J, et al. Investigators C. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017 ; 377 : 1319-30.
pubmed

18) Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT-ACS study. Circ J. 2014 ; 78 : 1684-92.
pubmed

19) Goto S. Global trial or local one? Circulation. 2019 ; 140 : 1878-80.

20) Wiviott SD, Braunwald E, McCabe CH, et al. Investigators T-T. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 : 2001-15.

21) Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 : 1045-57.
pubmed

22) Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome-randomized, double-blind, phase III PHILO study. Circ J. 2015 ; 79 : 2452-60.
pubmed

[ CHAPTER 2 ] 動脈系の血栓症と静脈系の血栓症から考える診断と治療の「正解」

P.102 掲載の参考文献

1) 後藤信一, 後藤信哉. 人工知能の真実-AIは医療を変えるわけではない? (J-CLEAR通信 (101)). 日本医事新報. 2019 ; 4956 : 40-3.

2) Goto S, Goto S, Pieper KS, et al. Investigators ftG-A. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists : GARFIELD-AF. Eur Heart J-Cardiovasc Pharmacother. 2020 ; 6 : 301-9.

3) Gurbel PA, Serebruany VL. Oral platelet IIb/IIIa inhibitors : from attractive theory to clinical failures. J Thromb Thrombolysis. 2000 ; 10 : 217-20.
pubmed

4) Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 ; 324 : 781-8.

5) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction : ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988 ; 2 : 349-60.

6) Goto S, Oka H, Ayabe K, et al. Prediction of binding characteristics between von Willebrand factor and platelet glycoprotein Ibalpha with various mutations by molecular dynamic simulation. Thromb Res. 2019 ; 184 : 129-35.
pubmed

はじめての方へ

個人／法人会員登録のご案内